CORRESP Filing
ACADIA PHARMACEUTICALS INC
Date: May 21, 2025 · CIK: 0001070494 · Accession: 0001193125-25-123577
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-287145
Letter
Re: Acadia Pharmaceuticals Inc. Registration Statement on Form S-3 Filed: May 9, 2025 File No. 333-287145 Ladies and Gentlemen: Acadia Pharmaceuticals Inc. (the “ Registrant ”) hereby requests that the U.S. Securities and Exchange Commission (the “ Commission ”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on May 23, 2025, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes Carlos Ramirez and Nicholaus Johnson of Cooley LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Carlos Ramirez of Cooley LLP at (858) 550-6157 or, in his absence, Nicholaus Johnson of Cooley LLP at (858) 550-6198. [ Signature Page Follows ]
A CADIA P HARMACEUTICALS I NC . 12830 El Camino Real, Suite 400 San Diego, California 92130 May 21, 2025 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. Street N.E. Washington, D.C. 20549-3010 Attention: Alan Campbell
Very truly yours,
ACADIA PHARMACEUTICALS INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP A CADIA P HARMACEUTICALS I NC . 12830 El Camino Real, Suite 400 San Diego, California 92130 May 21, 2025 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. Street N.E. Washington, D.C. 20549-3010 Attention: Alan Campbell Re: Acadia Pharmaceuticals Inc. Registration Statement on Form S-3 Filed: May 9, 2025 File No. 333-287145 Ladies and Gentlemen: Acadia Pharmaceuticals Inc. (the “ Registrant ”) hereby requests that the U.S. Securities and Exchange Commission (the “ Commission ”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on May 23, 2025, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes Carlos Ramirez and Nicholaus Johnson of Cooley LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Carlos Ramirez of Cooley LLP at (858) 550-6157 or, in his absence, Nicholaus Johnson of Cooley LLP at (858) 550-6198. [ Signature Page Follows ] Very truly yours, ACADIA PHARMACEUTICALS INC. By: /s/ Catherine Owen Adams Name: Catherine Owen Adams Title: Chief Executive Officer cc: Carlos Ramirez, Cooley LLP Nicholaus Johnson, Cooley LLP Jennifer Rhodes, Acadia Pharmaceuticals Inc. [C OMPANY S IGNATURE P AGE TO A CCELERATION R EQUEST ]